The role for TLR7 in SLE pathogenesis has been well-established, and currently, TLR7 is being evaluated as a drug target for SLE treatment (Fukui et al, 2018; Souyris et al, 2019; Wang et al, 2022). This evidence concerns the gene TLR7 and systemic lupus erythematosus.